logo
welcome
Investor's Business Daily

Investor's Business Daily

TG Therapeutics stock soars after study shows 92% of patients who took multiple sclerosis drug didn't progress to disability

Investor's Business Daily
Summary
Nutrition label

79% Informative

TG Therapeutics stock jumped more than 2% to 25.70 in early trading Wednesday .

The biotech company said 92% of patients who took its multiple sclerosis drug, Briumvi , didn't progress to disability after five years .

The annualized relapse rate over the course of five years was 0.02 , the equivalent to one relapse occurring in 50 years .

VR Score

82

Informative language

87

Neutral language

44

Article tone

formal

Language

English

Language complexity

47

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links